aAllergology Section, A Coruña University Hospital Complex, Spain
bPediatrics Department, Zaragoza Hospital, Spain
cDepartment of Biostatistics, A Coruña University Hospital Complex, Spain
dPrimary Care Pediatrics, A Coruña, Spain
ePrimary Care Pediatrics, Zaragoza, Spain
Introduction: Allergic rhinitis (AR) is a clinical syndrome characterized by IgE-mediated inflammation of the nasal mucosa. The present study investigates the quality of life (QoL) with AR among adults, using widely validated questionnaires, unlike in pediatric patients.
Materials and methods: A cross-sectional descriptive observational study was conducted, analyzing the QoL of 102 children with AR aged between 10-15 years, belonging to two health centers (HC) in Zaragoza and two HC in Coruña. The comparison of means between the two groups is carried out using the Student's test or the Mann-Whitney test, considering a value of p˂0.05 to be significant.
Results: Around 102 children were studied, with a majority (59.8%) being male and a mean age of 12 years. Around 76.5% have a family history of atopy. It was found that AR is more prevalent in Zaragoza (p ˂0.005), and asthmais highly prevalent in Coruña (p ˂0.001). The most important sensitizations are pollen in Zaragoza (p ˂0.05) and dust mites in A Coruña (p ˂0.001). More treatment needs and associated comorbidities (p˂0.05) were observed in A Coruña. The results of the ESPRINT-15 show that 63% of the patients have a good QoL, 27% fair, and 8.8%, poor. Those sensitized to mites have a worse score (p = 0.02). It was found that 52% of children experienced improvement during home confinement, with no notable differences between the two populations. The use of the mask favored QoL in patients from Zaragoza (p ˂0.001).
Conclusion: It was concluded that AR influences the QoL in pediatric patients. Greater QoL involvement, need for treatment, and comorbidities are observed in patients sensitized to dust mites compared to those sensitized to pollens. It was also observed that masks improved the symptoms, stopping patients being sensitized to pollens.
Key words: ESPRINT-15, rhinitis, quality of life, childhood allergy, HRQoL, SarsCov-2, prevention
*Corresponding author: Raquel López Rodríguez, Department of Allergology, A Coruña University Hospital Complex, As Xubias, 84. 15006, A Coruña, Spain. Email address: [email protected]
Received 14 March 2022; Accepted 1 May 2022; Available online 1 September 2022
Copyright: López-Rodríguez R, et al.
License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/
Allergic rhinitis (AR) is defined as an IgE-mediated inflammation of the nasal mucosa after exposure to a given allergen in previously sensitized individuals.1 The current epidemiological studies show a clear increase in the prevalence of AR in developed countries, affecting nearly 25% of the general population. According to data from the International Study of Asthma and Allergies in Childhood (ISAAC), in Spain, 8.5% of children aged 6-7 years and 16.3% of those aged 13-14 years report having had symptoms of allergic rhinitis during the last year.2
The predominant allergens are dust mites (in warm and humid coastal areas) and pollens (more important in inland areas), with grasses being the main cause of allergic asthma worldwide, including Spain.3 The pollination period is from March to August.3-5 Olive pollination is usually from the month of March to May.5 The cupresaceae pollinate from January to June, with a peak in February and March,5 and the salsola pollinate from March to October, with peaks in August and September. Fungi and pets are also common causes of allergy to inhalants among children.
Although the predominant pollination season is spring, the pollen calendar covers the entire year. In addition, there are important geographical differences, both in the prevalence of AR (10.1% in Barcelona compared to 22.2 and 23.3% in Asturias and Madrid, according to data from the ISAAC study for children aged 6-7 years), and in the predominant allergic sensitization profile7 (seasonal-pollen in the interior of the country and perennial-acarine in coastal regions).3
Currently, the classification proposed by the AR and its impact on asthma (ARIA) initiative, validated in Spain for use in pediatric patients is followed.10 The diagnosis is fundamentally clinical based on a correct anamnesis, and it is necessary to carry out an allergy study.11 The treatment is based on identifying and eliminating specific allergens and the use of medication to control symptoms.1
In recent years, AR has gained considerable relevance as a global health problem.12,13 It negatively influences the school performance and work productivity, since it decreases attention and concentration, and affects the social life of patients. It constitutes a very important risk factor for the subsequent development of asthma and other comorbidities.14 The measurement of health-related quality of life (HRQoL) is one of the most innovative aspects of the evaluation of AR in recent years, occupying an important role in the objectives for the control of the disease.13
Although there are numerous questionnaires to assess QoL, most have been developed in Anglo-Saxon countries. Thus, one of the main limitations is adaptation to other cultures, like Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), since cultural background and semantics are very important for validation.15 There is only one questionnaire that is designed and developed entirely in Spain: the ESPRINT questionnaire (Spanish study of quality of life in patients with rhinoconjunctivitis). It is the most widely used one in the Spanish population due to the fact that it is well-adapted to the culture of the country. The ESPRINT comes in two validated versions, a 28-item long version for research, and a shorter 15-item version (ESPRINT-15) to be used in clinical practice.16 The suitability of the ESPRINT-15 questionnaire as an instrument for measuring HRQoL in Spanish adults with allergic rhinitis has been verified. However, there is no validated questionnaire for the Spanish child population. So, we have adapted the ESPRINT-15 for better compression and applicability in children, as shown in Figure 1.16 The repercussion in the daily life of patients with AR is often neglected from an exclusively clinical analysis. Here, the QoL questionnaires are constituted as an indispensable instrument to evaluate the true scope of it.17
Figure 1 ESPRINT-15 modified in the pediatric population.
Therefore, the main objective of the study was to understand whether the quality of life (QoL) of pediatric patients with AR in our environment was affected. The secondary objectives were to determine whether there were differences in QoL depending on geographical location and the type of allergen involved, and to assess whether prevention measures against the COVID-19 pandemic influence the quality of life of pediatric patients with AR.
A cross-sectional descriptive observational study is carried out whose main objective is to evaluate the QoL of children with AR belonging to several health centers (HC) (2 in A Coruña and 2 in Zaragoza) with exposure to different types of aeroallergens.
All patients of the study had to be diagnosed with AR, should be between 10-15 years of age, and must have signed the informed consent after being explained the information sheet. Those patients who presented some concomitant chronic pathology not associated with AR, with an impact on morbidity and mortality that affected the patient's QoL, as well as any pathology or degree of immaturity that prevented the correct understanding and/or answering of the questionnaire, were excluded. The parents of the included patients duly completed the informed consent form prior to the completion of the questionnaire.
The data collection was carried out on patients who came to the consultation consecutively until the necessary sample was covered, which began once permission was obtained from the Ethics and Research Committee of the Community of Aragon (CP/CI:PI20/600). The data collection period was February-April 2021. The participation rate of the selected patients was 100%.
The ESPRINT-15 questionnaire contains 15 items overall, and the score for each item was obtained. The global score and the dimensional scores ranges from 0 (no impact on HRQoL) to 6 (maximum impact on HRQoL). The application consists of asking the child what he/she has noticed in the last 15 days. In addition, 2 questions have been added to assess the influence of prevention measures against the SarsCov2 virus on the QoL of RA in our patients, as shown in Figure 1.
A descriptive analysis was performed. The association between qualitative variables is estimated using the Chi-square statistical test or Fisher’s test. For the comparison of means between two groups, the Student’s t-test or the Mann-Whitney test was performed, and for more than two groups, the ANOVA test or the Kruskal-Wallis test was used. Correlation between quantitative variables is found with Pearson’s or Spearman’s correlation coefficient. The statistical software used was “IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp.
The sample is made up of 102 patients, with the same number of patients each in Coruña and Zaragoza, i.e., 51 patients. There is a predominance of males (59.8%) compared to females (40.2%), with a mean age of 12.1 years (±1.41 years). Around 76.5% of the patients have a family history of atopy of which 35.3% correspond to AR, with higher prevalence in Zaragoza (p=0.03); 15.7% have asthma, which is more prevalent in Coruña (p˂0.01); 14.7% had both the antecedents and 10.8% have other antecedents such as atopic dermatitis (AD) or food allergies. Around 59% of patients have some comorbidity, such as asthma (35%) or AD (26%), being more prevalent in Coruña (p˂0.05).
In the main pollens, a clear predominance of affectation is observed in Zaragoza compared to Coruña (p˂0.05), unlike what occurs in the case of mites, where it predominates in Coruña (p˂0.001). With respect to animal epithelia, there are no statistically significant differences between both the populations, as shown in Figure 2.
Figure 2 Prevalence of sensitization to different allergens by province.
Around 92.2% of patients receive treatment to control the symptoms, with oral antihistamines being the most used (86.3%), above nasal corticosteroids (59.8%), eye drops (24.5%), inhaled therapy (22.5%), and immunotherapy (14.7%). In Coruña, a greater use of CIN, inhaled therapy, especially immunotherapy was observed than in Zaragoza (p˂0.05), as shown in Figure 3.
Figure 3 Treatments used by province.
Regarding the QoL of the patients assessed through the ESPRINT-15m questionnaire, 63.7% of the patients obtained an assessment of good QoL, 27.5% regular QoL, and 8.8% poor QoL. At a subjective level, these percentages vary, obtaining a perception of good QoL of up to 86.1%, compared to 2% of poor QoL. The mean score obtained was 22.8 ± 19.9 points. The total score of the ESPRINT-15m questionnaire was higher in Coruña (mean of 26.3 points) than in Zaragoza (mean of 19.2 points) with p= 0.02, as shown in Figure 4.
Figure 4 Box plot showing the distribution of scores by provinces.
Breaking down the ESPRINT questionnaire, the significance level was calculated with the Bonferoni correction; Zaragoza patients had less nasal obstruction (p˂0.05), less ocular itching (p˂0.05), and less respiratory difficulty (p ˂0.05) as well as less difficulty falling asleep (p˂0.05).
Given the current epidemic situation caused by COVID-19, it was considered appropriate to investigate how the preventive measures adopted influenced the QoL of patients with AR. Around 35.3% of the patients appreciated the improvement in AR-related symptoms with the use of a mask, and up to 52% with home confinement. When evaluating the effect of the mask in patients with AR, it was observed that 52.9% of the patients in Zaragoza perceived a symptomatic improvement; however, in Coruña this percentage drops to 17.6 (p˂0.001). In contrast, the confinement measures do not show statistically significant differences between both the populations.
According to the ARIA guidelines, AR is classified as intermittent, mild persistent, moderate persistent, and severe persistent.18 No statistically significant differences have been found between both populations.
AR is highly prevalent in our environment, and it is expected to increase in the coming years. Although it is not a serious condition, it is a chronic respiratory disease with great socioeconomic and health impact, causing a real public health problem.17,19 It is essential to diagnose it in order to carry out an adequate treatment and provide an optimal QoL. One of the tools we have to optimize the approach to AR are HRQoL questionnaires. However, unlike what happens with the adult population, there is little literature that refers to HRQoL in pediatric patients.20,21
Through the questionnaire, a very rigorous and highly reproducible mathematical analysis was made. This way we can reliably compare how the quality of life of the patients is affected. In other words, the importance of these determinations is that, thanks to them, the patient's opinion regarding their disease, their fears or concerns, as well as the limitations it provides, are known in a systematic and numerically quantified way.16 The slight predominance of affected males in our sample coincides with other studies that show an OR of 1.9 between both sexes, although it becomes equal when they reach adulthood.7 The existence of a family history of atopy in more than 75% supports the influence of the genetic factor in the development of AR, as reflected in various studies.7,22
As reflected in the studies on the geographical distribution of aeroallergens6 in Coruña, there is a higher prevalence of sensitization to mites (p˂0.001), while in Zaragoza the prevalence is higher to pollens (p˂0.05). This makes it possible to associate the population of Coruña with exposure mainly to mites and to Zaragoza with pollen, making it possible to make comparisons between both aeroallergens.
The total score of both the populations reflect a good QoL (˂28 points), although it is true that the total score is higher in Coruña than in Zaragoza, which suggests a greater deterioration in QoL in patients sensitized to mites compared to those sensitized to pollens. This trend is repeated in practically all the items of the questionnaire, demonstrating better QoL control in patients sensitized to pollens. However, the width of the standard deviations indicates the existence of significant heterogeneity when it comes to affecting the QoL of the patients. A non--negligible percentage of patients (36.3%) obtained scores greater than 28, which would correspond to a poorly controlled AR.
In addition, the prevalence of comorbidities such as asthma present in patients sensitized to mites coincides with a worse score, which is in harmony with the literature described, where the prevalence of comorbidities reaches 40% in the case of asthma and up to 70% of atopic dermatitis.23,24 However, it may also be due to the influence of the mite as a persistent aeroallergen compared to the intermittent aeroallergens that predominate in Zaragoza, and that therefore, are more dependent on the time of data collection.6
With regard to symptomatic treatment, it should be noted that the use of oral antihistamines is more frequent than CIN in both populations, despite the latter being the treatment of first choice.25 The difference in the use of inhaled therapy and immunotherapy also stands out, being clearly more frequent in those sensitized to mites (p˂0.05) largely due to the higher prevalence of asthma in this sample, as has been cited above.23
Regarding the current epidemiological situation concerning the global health crisis caused by the coronavirus, as it might be expected, the feeling of improvement in QoL with the use of a mask was statistically significantly better in Zaragoza than in Coruña. It is so since there is a greater exposure to outdoor allergens, and masks partially avoid contact of the aeroallergen with the patient. However, the same does not occur with the confinement factor, where a statistically significant higher prevalence of worsening was expected to be found in Coruña, where the sample is more exposed to indoor aeroallergens. No evidence of this fact has been found in the reviewed literature.
One of the possible limitations of this study is the chronology, since a part of the allergens involved in the development of AR, mainly pollens, are subject to their pollination period. Lastly, it would be interesting to have new studies that allow us to assess the true extent of QoL involvement in pediatric patients, and to do so, we should have validated questionnaires such as the SPRINT-15 for the Spanish child population.
AR influences QoL in pediatric patients. A greater affectation is observed in coastal the populations where mites predominate, than in inland populations where pollens predominate. There is an important family influence when developing RA. It was found that the use of a face mask subjectively improves the symptoms of AR in those patients exposed to outdoor aeroallergens. The clinical worsening of AR cannot be related to home confinement in patients sensitized to indoor aeroallergens.
1. Bercedo Sanz M, Callén Blecua M, Guerra Pérez A, Praena Crespo M, Luis Montón Álvarez J, Mora Gandarillas I, et al. GVR Protocols (P-GVR-6) Allergic Rhinitis. Asoc Española Pediatrics Primary Care. 2016.
2. Spanish GI. Prevalence of symptoms suggestive of allergic rhinitis and atopic dermatitis in adolescents (ISAAC Spain Study). An Esp Pediatr. 1999;51(4):369–76.
3. Arnedo-Pena A, García-Marcos L, García Hernández G, Aguinagua Ontoso I, González Díaz C, Morales Suárez-Varela M, et al. Temporal trend and geographical variations of the prevalence of allergic rhinitis symptoms in schoolchildren aged 6-7 years from eight Spanish areas, according to the ISAAC. An Pediatr. 2005;62(3):229–36. 10.1157/13071837
4. Judges CR. Animals and others. Avoidance measures. 2019;(1): 65–85.
5. Aerobiology Committee. [Internet]. SEAIC. 2021. Available from: https://www.polenes.com/en/home
6. Rossen RD, Birdsall HH. Allergy and immunology. Internal Med Secrets. 2006;6(1):451–10. 10.1016/B978-84-8174-886-4.50012-X
7. Lucas Moreno JM, Moreno Salvador AO, Ortega Bernal MG Allergic pathology of the upper respiratory tract. Protoc diagn ter pediatr. 2019;2:133-48.
8. Colomer MC. Allergic rhinitis. Offarm. 2004;23:146–7.
9. Service E, Immunology D, Pediatric A, Integrated U. Allergic rhinoconjunctivitis. 2013;(8):564–73. 32
10. Montoro J, Del Cuvillo A, Mullol J, Molina X, Bartra J, Dávila I, et al. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: The PEDRIAL study. Allergy Eur J Allergy Clin Immunol. 2012;67(11):1437–42. 10.1111/all.12011
11. Schuler IV CF, Montejo JM. Allergic Rhinitis in Children and Adolescents. Pediatr Clin North Am [Internet]. 2019;66(5):981–93. 10.1016/j.pcl.2019.06.004
12. GEMA 5.0. Guía española para el manejo del asma. Spanish Society of Pulmonology and Thoracic Surgery. 5th. ed. Maidenhead: Luzán 5 Health Consulting, S.A. 2021
13. Valls-Mateus M, Marino-Sanchez F, Ruiz-Echevarría K, Cardenas-Escalante P, Jiménez-Feijoo R, Blasco-Lozano J, et al. Nasal obstructive disorders impair health-related quality of life in adolescents with persistent allergic rhinitis: A real-life study. Pediatr Allergy Immunol. 2017;28(5):438–45. 10.1111/pai.12724
14. Sobrevia Elfau MT, Ferrer Clavería L, Rojas Hijazo B, Colás Sanz C. Quality of life in allergic rhinitis. ENT Aragon. 2009;12(1):9–14.
15. Ivette M, Hernández M, Reyes HM, Margarita A, Rodríguez C, Reyes CM, et al. Original article Evaluation of the quality of life in patients with allergic rhinitis. Quality. 2009;54:102–8.
16. Valero A, Baró E, Sastre J, Navarro-Pulido AM, Izquierdo I, Martí-Guadaño E, et al. Reference values for facilitating the interpretation of the ESPRINT-15 Questionnaire (Spanish Version). J Investig Allergol Clin Immunol. 2009;19(5):396–3.
17. Cedeño-Zavalu VM, Alonso-Muñiz GR, Quijije-Segovia SK, Sornoza-Pin AA, Cepeda-García LP, Castillo-Chávez KD. Estrategias para una calidad de vida en pacientes con rinitis alérgicas. Dom Cien. 2018;4:255–269. 10.23857/dc.v4i4.839
18. Izquierdo-Domínguez A, Valero AL, Mullol J. Comparative analysis of allergic rhinitis in children and adults. Curr Allergy Asthma Rep. 2013;13(2):142–51. 10.1007/s11882-012-0331-y
19. Blaiss MS, Hammerby E, Robinson S, Kennedy-Martin T, Buchs S. The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: A literature review. Ann Allergy, Asthma Immunol. 2018;121(1):43–52. 10.1016/j.anai.2018.03.028
20. Devillier P, Bousquet PJ, Grassin-Delyle S, Salvator H, Demoly P, Bousquet J, et al. Comparison of outcome measures in allergic rhinitis in children, adolescents and adults. Pediatr Allergy Immunol. 2016;27(4):375–81. 10.1111/pai.12561
21. Silva MGN, Naspitz CK, Solé D. Evaluation of quality of life in children and adolescents with allergic rhinitis: Adaptation and validation of the rhinoconjunctivitis quality of life questionnaire (RQLQ). Allergol Immunopathol. 2001;29(4):111–8. 10.1016/S0301-0546(01)79042-8
22. Begin P, Nadeau KC. Epigenetic regulation of asthma and allergic disease. Allergy, Asthma Clin Immunol. 2014;10(1):1–12. 10.1186/1710-1492-10-27
23. Meltzer EO. allergic rhinitis. Burden of Illness, Quality of Life, Comorbidities, and Control. Immunol Allergy Clin North Am. 2016;36(2):235–48. 10.1016/j.iac.2015.12.0
24. Mastrorilli C, Posa D, Cipriani F, Caffarelli C. Asthma and allergic rhinitis in childhood: what's new. Pediatr Allergy Immunol. 2016;27(8):795–803. 10.1111/pai.12681
25. Dykewicz MS, Wallace D V, Amrol DJ, Baroody FM, Bernstein JA, Craig TJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol. 2020;146(4):721–67. 10.1016/j.jaci.2020.07.007